<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02487732</url>
  </required_header>
  <id_info>
    <org_study_id>Adenosine diphosphate blockers</org_study_id>
    <nct_id>NCT02487732</nct_id>
  </id_info>
  <brief_title>Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <brief_summary>
    <textblock>
      To investigate pleiotropic effects of ticagrelor in addition to its antiplatelet effects in
      type 2 diabetic patients with non-ST elevation acute coronary syndrome by measuring
      inflammatory markers, circulating number of endothelial progenitor cells, brachial artery
      endothelial function, and arterial stiffness.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2015</start_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in circulating number of endothelial progenitor cells</measure>
    <time_frame>Expected average of 5 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in brachial artery flow mediated dilation</measure>
    <time_frame>Expected average of 5 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite measure of brachial-ankle pulse wave velocity, and augmentation index.</measure>
    <time_frame>Expected average of 5 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>180mg loading dose, 90mg twice daily for 5 weeks, then crossover to prasugrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60mg loading dose, 10mg once daily for 5 weeks, then crossover to ticagrelor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor 90mg twice daily for 5 weeks</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Prasugrel 10mg once daily for 5 weeks</description>
    <arm_group_label>Prasugrel</arm_group_label>
    <other_name>Effient</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of informed consent prior to any study specific procedures

          2. Newly diagnosed type 2 diabetic patients or type 2 diabetic patients on hypoglycemic
             agents between the age of 30 to 70

          3. Non-ST elevation Acute coronary syndrome with successful coronary stent implantation
             (with TIMI flow grade 3 after the procedure)

        Exclusion Criteria:

          1. Hypersensitivity to ticagrelor, prasugrel or any of the excipients

          2. No prior use of either ticagrelor or prasugrel within a month prior to randomization.

          3. History of intracranial bleeding at any time

          4. Active pathologic bleeding

          5. Hemoglobin A1c &gt;9%

          6. Type 1 diabetes

          7. Decreased serum platelet level (&lt; 100,000/uL)

          8. Need for chronic oral anticoagulant therapy or chronic low-molecular-weight heparin

          9. Gastrointestinal bleed within the past 6 months, or major surgery within 30 days

         10. Renal failure requiring dialysis or anticipated need for dialysis during the course of
             the study

         11. Any condition which in the opinion of the investigator would make it unsafe or
             unsuitable for the patient to participate in this study

         12. Involvement in the planning and/or conduct of the study

         13. Left ventricular ejection fraction &lt; 40%

         14. Hepatic dysfunction (aspartate aminotransferase or alanine aminotransferase &gt; twice
             the upper limit)

         15. Gastrointestinal disorder such as Crohn`s disease

         16. Alcohol abuse

         17. Steroid or hormone replacement therapy

         18. Serum creatinine &gt; 2.0 mg/dL.

         19. Prior history of CVA or stroke

         20. Body weight &lt; 60 kg

         21. Life expectancy less than a year

         22. Known pregnancy, breast-feeding, or intend to become pregnant during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2015</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>December 23, 2016</last_update_submitted>
  <last_update_submitted_qc>December 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Anam Hospital</investigator_affiliation>
    <investigator_full_name>Soon Jun Hong</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetic Patients With Non-ST Elevation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

